Hansoh Pharma Wins NMPA Breakthrough Status for Fourth-Gen Lung Cancer Drug

Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in secondsHansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has issued an update. Hansoh Pharmaceutical Group has secured breakthrough-therapy designation from China’s National Medical Products Administration for HS-10504, its self-developed fourth-generation EGFR tyrosine kinase inhibitor. The oral therapy is proposed for patients with locally advanced or metastatic non-small cell lung cancer carrying the EGFR C797S mutation following failure of prior EGFR-TKI treatment. The designation is expected to accelerate the development and regulatory review of HS-10504, underscoring Hansoh’s push into next-generation targeted lung cancer therapies. It also reinforces the company’s positioning in China’s competitive oncology drug market by addressing a hard-to-treat patient segment with limited existing options. The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page. More about Hansoh Pharmaceutical Group Company Limited Hansoh Pharmaceutical Group Company Limited is a China-based biopharmaceutical company focused on the research, development and commercialization of innovative therapies. The group develops small-molecule drugs and other treatments targeting major diseases, with a growing oncology portfolio aimed at lung cancer and other high-incidence conditions in the domestic market. Average Trading Volume: 9,584,812 Technical Sentiment Signal: Buy Current Market Cap: HK$203.8B For an in-depth examination of 3692 stock, go to TipRanks’ Overview page.